Free Trial

Olema Pharmaceuticals (OLMA) News Today

→ No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad)
Free OLMA Stock Alerts
$13.13
-0.16 (-1.20%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 8 at 5:48 AM | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down to $13.92
June 8 at 2:12 AM | americanbankingnews.com
Analysts Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $22.00
June 7 at 10:32 PM | marketbeat.com
Sectoral Asset Management Inc. Reduces Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Sectoral Asset Management Inc. lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 95.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,230 shares of the company's stock after
June 6 at 7:32 AM | insidertrades.com
Cyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock
June 6 at 6:02 AM | americanbankingnews.com
Cyrus Harmon Sells 15,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock
June 6 at 1:26 AM | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 3.2% on Insider Selling
June 5 at 10:17 AM | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.2% on Insider Selling
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.2% After Insider Selling
June 5 at 3:56 AM | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Given Buy Rating at HC Wainwright
June 5 at 1:22 AM | marketbeat.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Buy" from Brokerages
Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month
June 4, 2024 | marketbeat.com
Insider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells 5,000 Shares of Stock
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 5,000 shares of the company's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $10.93, for a total transaction of $54,650.00. Following the completion of the transaction, the director now owns 786,283 shares of the company's stock, valued at $8,594,073.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
June 4, 2024 | globenewswire.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 4, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 9.2%
Olema Pharmaceuticals (NASDAQ:OLMA) Trading 9.2% Higher
June 4, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Tuesday.
June 3, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $9.68
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $9.68
May 28, 2024 | globenewswire.com
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 21, 2024 | barrons.com
Olema Pharmaceuticals Inc.
May 20, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.6%
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 3.6%
May 17, 2024 | marketbeat.com
Q2 2024 Earnings Estimate for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Issued By HC Wainwright
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Olema Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.50) pe
May 16, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination
May 16, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Olema Pharmaceuticals Amid Promising Clinical Trial Results for Breast Cancer Therapy
May 16, 2024 | markets.businessinsider.com
Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals’ Drug Combination in Clinical Studies
May 16, 2024 | markets.businessinsider.com
Promising Combination Therapy Drives Buy Rating for Olema Pharmaceuticals
May 15, 2024 | markets.businessinsider.com
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
May 15, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.17
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.17
May 15, 2024 | globenewswire.com
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
May 14, 2024 | marketbeat.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Victory Capital Management Inc.
Victory Capital Management Inc. boosted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 879.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 621,527 share
May 10, 2024 | marketbeat.com
Olema Pharmaceuticals, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.52) Per Share (NASDAQ:OLMA)
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at Lifesci Capital issued their Q3 2024 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 8th. Lifesci Capital analyst S. Slutsky forecasts that the
May 10, 2024 | markets.businessinsider.com
Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position
May 9, 2024 | markets.businessinsider.com
Buy Rating on Olema Pharmaceuticals: Financial Stability and Promising Drug Development Fuel Positive Outlook
May 9, 2024 | markets.businessinsider.com
Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration
May 8, 2024 | investorplace.com
OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024
May 8, 2024 | globenewswire.com
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024 | globenewswire.com
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 8, 2024 | insidertrades.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 5,000 Shares
May 3, 2024 | insidertrades.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $142,650.00 in Stock
May 2, 2024 | marketbeat.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 15,000 Shares
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 15,000 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total value of $142,650.00. Following the completion of the sale, the director now owns 811,283 shares of the company's stock, valued at $7,715,301.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
May 2, 2024 | globenewswire.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2024 | globenewswire.com
Olema Oncology to Participate in Upcoming Investor Conferences in May
April 21, 2024 | finance.yahoo.com
Olema Pharmaceuticals, Inc. (OLMA)
April 18, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%
April 12, 2024 | markets.businessinsider.com
Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge
April 10, 2024 | bizjournals.com
How Olema Oncology moved from layoffs to pivotal cancer drug studies
April 8, 2024 | globenewswire.com
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 2, 2024 | globenewswire.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89
April 2, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs Group
The Goldman Sachs Group assumed coverage on Olema Pharmaceuticals in a report on Tuesday. They issued a "buy" rating and a $24.00 price objective for the company.
April 1, 2024 | marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 5.4% After Insider Selling
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.4% on Insider Selling
March 30, 2024 | insidertrades.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $219,400.00 in Stock
March 29, 2024 | marketbeat.com
Insider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells 20,000 Shares of Stock
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $10.97, for a total value of $219,400.00. Following the completion of the sale, the director now directly owns 826,283 shares of the company's stock, valued at approximately $9,064,324.51. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
March 28, 2024 | seekingalpha.com
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.

After Conviction, More Bad News for Trump (Ad)

As a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.

Click here to see the details because this coming election meltdown could trigger…

OLMA Media Mentions By Week

OLMA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OLMA
News Sentiment
▼
0.53

0.73
▲
Average
Medical
News Sentiment

OLMA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OLMA Articles
This Week
▼
17

3
▲
OLMA Articles
Average Week

Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:OLMA) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners
Millionaire-Making “Wealth Pattern” Just Repeated on April 22
If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.
Paradigm Press | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
AI Hell Will Break Loose [June 30, 2024] …
On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...
Banyan Hill Publishing | Sponsored
Was the Great Financial Crisis fun?
The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...
Brooks Enterprises | Sponsored
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored